A Phase II Study of DAB 389 IL-2, an Interleukin-2 Fusion Toxin, for Previously Treated Stage II, III, and IV Follicular Low-Grade Non-Hodgkin's Lymphoma.

Trial Profile

A Phase II Study of DAB 389 IL-2, an Interleukin-2 Fusion Toxin, for Previously Treated Stage II, III, and IV Follicular Low-Grade Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2010

At a glance

  • Drugs Denileukin diftitox (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2010 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
    • 02 Feb 2010 Planned number of patients changed from 43 to 77 as reported by ClinicalTrials.gov.
    • 17 Feb 2009 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top